Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26:417-422
Published online before print December 8, 2005, doi: 10.1161/01.ATV.0000199519.37089.a0
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
26/2/417    most recent
01.ATV.0000199519.37089.a0v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ferreira, I. A.
Right arrow Articles by Akkerman, J.-W. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ferreira, I. A.
Right arrow Articles by Akkerman, J.-W. N.
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26:417.)
© 2006 American Heart Association, Inc.


Thrombosis

Platelet Inhibition by Insulin Is Absent in Type 2 Diabetes Mellitus

Irlando Andrade Ferreira; Astrid I.M. Mocking; Marion A.H. Feijge; Gertie Gorter; Timon W. van Haeften; Johan W.M. Heemskerk; Jan-Willem N. Akkerman

From the Laboratory for Thrombosis and Haemostasis (I.A.F., A.I.M.M., G.G., J.-W.N.A.), Department of Hematology, University Medical Center Utrecht and the Institute for Biomembranes (I.A.F., A.I.M.M., G.G., J.-W.N.A.), Utrecht University, the Netherlands; Department of Biochemistry and Human Biology (M.A.H.F., J.W.M.H.), University of Maastricht, the Netherlands; Department of Internal Medicine (T.W.v.H.), University Medical Center Utrecht, the Netherlands.

Correspondence to Dr J.W.N. Akkerman, Thrombosis and Haemostasis, Department of Hematology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, the Netherlands. E-mail j.w.n.akkerman{at}azu.nl

Objective— ADP-induced P2y12 signaling is crucial for formation and stabilization of an arterial thrombus. We demonstrated recently in platelets from healthy subjects that insulin interferes with Ca2+ increases induced by ADP-P2y1 contact through blockade of the G-protein Gi, and thereby with P2y12-mediated suppression of cAMP.

Methods and Results— Here we show in patients with type 2 diabetes mellitus (DM2) that platelets have lost responsiveness to insulin leading to increased adhesion, aggregation, and procoagulant activity on contact with collagen. Using Ser473 phosphorylation of protein kinase B as output for insulin signaling, a 2-fold increase is found in insulin-stimulated normal platelets, but in DM platelets there is no significant response. In addition, DM2 platelets show increased P2y12-mediated suppression of cAMP and decreased P2y12 inhibition by the receptor antagonist AR-C69931MX.

Conclusion— The loss of responsiveness to insulin together with increased signaling through P2y12 might explain the hyperactivity of platelets in patients with DM2.

Insulin inhibits Ca2+ mobilization in platelets by interfering with P2y12-mediated cAMP suppression. Here we show that DM2 platelets have lost responsiveness to insulin and also show increased P2y12 signaling. This might explain the increased platelet deposition and procoagulant activity under flow of DM2 platelets on contact with collagen.


Key Words: P2y12 receptor • Ca2+ regulation • clopidogrel • protein kinase B/Akt • IRS-1




This article has been cited by other articles:


Home page
Diabetes CareHome page
D. J. Angiolillo
Antiplatelet Therapy in Diabetes: Efficacy and Limitations of Current Treatment Strategies and Future Directions
Diabetes Care, April 1, 2009; 32(4): 531 - 540.
[Full Text] [PDF]


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
R. B. Matondo, C. Punt, J. Homberg, M. J. M. Toussaint, R. Kisjes, S. J. A. Korporaal, J. W. N. Akkerman, E. Cuppen, and A. de Bruin
Deletion of the serotonin transporter in rats disturbs serotonin homeostasis without impairing liver regeneration
Am J Physiol Gastrointest Liver Physiol, April 1, 2009; 296(4): G963 - G968.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
V. Fuster and M. E. Farkouh
Acute Coronary Syndromes and Diabetes Mellitus: A Winning Ticket for Prasugrel
Circulation, October 14, 2008; 118(16): 1607 - 1608.
[Full Text] [PDF]


Home page
CirculationHome page
S. D. Wiviott, E. Braunwald, D. J. Angiolillo, S. Meisel, A. J. Dalby, F. W.A. Verheugt, S. G. Goodman, R. Corbalan, D. A. Purdy, S. A. Murphy, et al.
Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38
Circulation, October 14, 2008; 118(16): 1626 - 1636.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
L. Ang, V. Palakodeti, A. Khalid, S. Tsimikas, Z. Idrees, P. Tran, P. Clopton, N. Zafar, G. Bromberg-Marin, S. Keramati, et al.
Elevated Plasma Fibrinogen and Diabetes Mellitus Are Associated With Lower Inhibition of Platelet Reactivity With Clopidogrel
J. Am. Coll. Cardiol., September 23, 2008; 52(13): 1052 - 1059.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
D. J. Angiolillo, P. Capranzano, S. Goto, M. Aslam, B. Desai, R. K. Charlton, Y. Suzuki, L. C. Box, S. B. Shoemaker, M. M. Zenni, et al.
A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study
Eur. Heart J., September 2, 2008; 29(18): 2202 - 2211.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Neuroradiol.Home page
S. Prabhakaran, K.R Wells, V.H. Lee, C.A. Flaherty, and D.K. Lopes
Prevalence and Risk Factors for Aspirin and Clopidogrel Resistance in Cerebrovascular Stenting
AJNR Am. J. Neuroradiol., February 1, 2008; 29(2): 281 - 285.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
D. J. Angiolillo, S. B. Shoemaker, B. Desai, H. Yuan, R. K. Charlton, E. Bernardo, M. M. Zenni, L. A. Guzman, T. A. Bass, and M. A. Costa
Randomized Comparison of a High Clopidogrel Maintenance Dose in Patients With Diabetes Mellitus and Coronary Artery Disease: Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) Study
Circulation, February 13, 2007; 115(6): 708 - 716.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
D. J. Angiolillo, E. Bernardo, C. Ramirez, M. A. Costa, M. Sabate, P. Jimenez-Quevedo, R. Hernandez, R. Moreno, J. Escaned, F. Alfonso, et al.
Insulin Therapy Is Associated With Platelet Dysfunction in Patients With Type 2 Diabetes Mellitus on Dual Oral Antiplatelet Treatment
J. Am. Coll. Cardiol., July 18, 2006; 48(2): 298 - 304.
[Abstract] [Full Text] [PDF]